Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Slides:

Advertisements

Similar presentations

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Advertisements

Changes in serum cortisol and prolactin associated with acupuncture during controlled ovarian hyperstimulation in women undergoing in vitro fertilization–embryo.

Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle Michael W.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Michele A. Hanson, M.D., Daniel A. Dumesic, M.D.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating.

Raoul Orvieto, M. D. , M. Sc. , Eduard Hod, M. D

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Hongxia Li, M. D. , Jiangang Chen, M. D. , James W Overstreet, M. D

Differences in in vitro fertilization (IVF) outcome between white and black women in an inner-city, university-based IVF program Fady I Sharara, M.D.,

Day 4 Estradiol Levels Predict Pregnancy Success in Women Undergoing Controlled Ovarian Hyperstimulation for IVF John Y Phelps, M.D., Adam S Levine,

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Zeev Shoham, M.D. Fertility and Sterility

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity Helen Sullivan,

Robert F. Casper, M.D. Fertility and Sterility

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Effect of letrozole at 2. 5 mg or 5

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.

Fertility and Sterility

Luteal estradiol administration strengthens the relationship between day 3 follicle- stimulating hormone and inhibin B levels and ovarian follicular status

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

Hongxia Li, M. D. , Steven T Nakajima, M. D. , Jiangang Chen, M. D

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Pyridostigmine cotreatment for controlled ovarian hyperstimulation in low responders undergoing in vitro fertilization–embryo transfer Chung-Hoon Kim,

Comparison of urinary and recombinant follicle-stimulating hormone in in vitro growth, maturation, and fertilization of mouse preantral follicles Giannina.

Human granulosa-lutein cell in vitro production of progesterone, inhibin A, inhibin B, and activin A are dependent on follicular size and not the presence.

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle- stimulating hormone containing the human chorionic gonadotropin carboxyterminal.

Anuja Dokras, M. D. , Ph. D. , Antonia Habana, M. D. , Juan Giraldo, M

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer Mohamed.

Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

A study of luteal phase expression of inhibin, activin, and follistatin subunits in the endometrium of women with recurrent miscarriage Alka Prakash,

Serum inhibin A, inhibin B, pro-αC, and activin A levels in women with idiopathic premature ovarian failure Winfried Munz, M.D., Mohamed Eid Hammadeh,

In vitro sildenafil citrate use as a sperm motility stimulant

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles David.

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.

Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic.

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

Use of recombinant human chorionic gonadotropin in ovulation induction

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Superoxide dismutase activity in human follicular fluid after controlled ovarian hyperstimulation in women undergoing in vitro fertilization Luca Sabatini,

Presentation transcript:

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment Fritz W Casper, M.D., Rudolf J Seufert, M.D., Michael Schaffrath, M.D., Kunhard Pollow, M.D. Fertility and Sterility Volume 75, Issue 1, Pages 32-37 (January 2001) DOI: 10.1016/S0015-0282(00)01637-X

Figure 1 Follicle size was significantly correlated (P<.01) with serum levels of pro alpha-C, inhibin A, inhibin B, and estradiol on day 7 of recombinant FSH treatment. Casper. Inhibins and activin in FSH stimulation. Fertil Steril 2001. Fertility and Sterility 2001 75, 32-37DOI: (10.1016/S0015-0282(00)01637-X)